MRNA therapy hopes to fix copper problem in wilson disease
Disease control
Recruiting now
This early-phase trial tests a new mRNA drug called DSL101 in 18 adults with Wilson disease, a genetic condition that causes copper buildup. The drug is designed to help the body produce a protein that controls copper. Participants receive low, medium, or high doses by IV every f…
Phase: EARLY_PHASE1 • Sponsor: DSciLab Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC